AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Acorda Reports Death in Parkinson's Trials, Stock Down 40%
by Zacks Equity Research
Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
by Zacks Equity Research
AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
by Arpita Dutt
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
by Zacks Equity Research
AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy
by Zacks Equity Research
Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day
by Arpita Dutt
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
by Zacks Equity Research
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
Foreign Stock Roundup: Toyota, Gol Linhas Beat, AstraZeneca, Fresenius Miss
by Swarup Gupta
Earnings numbers continued to guide Europe's markets last week.
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
by Arpita Dutt
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up
by Zacks Equity Research
Valeant (VRX) reported encouraging results for the third quarter but trimmed its guidance to reflect recent divestitures.
Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
by Zacks Equity Research
AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah
by Arpita Dutt
It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.
Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.
Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal
by Zacks Equity Research
Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.
Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong
by Zacks Equity Research
Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.
Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View
by Zacks Equity Research
Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.
Celgene Down on Discontinued Crohn's Disease Drug Study
by Zacks Equity Research
Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.
Cancer Treatment Update: Second Gene Therapy Receives Approval
by Zacks Equity Research
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
by Zacks Equity Research
AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.
Bristol-Myers Gets Priority Review for Opdivo Label Expansion
by Zacks Equity Research
Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.
Valeant Reports Positive Results on Psoriasis Drug Siliq
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.
Cancer Space Update: Lung & Breast Cancer Studies in Focus
by Zacks Equity Research
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Lilly's Verzenio Gets Priority Review in First-Line Setting
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.